A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa

Trial ID or NCT#

NCT03836001

Status

not recruiting iconNOT RECRUITING

Purpose

To determine if Serlopitant (when taken by mouth) is safe and works on itch in patients aged 13 and above with EB.

Official Title

A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Albert Sean Chiou, MD, MBA
Albert Sean Chiou, MD, MBA
Dermatologist, Cutaneous oncology specialist
Clinical Professor, Dermatology

Contact us to find out if this trial is right for you.

Contact

Clinical Trial Coordinator
650-721-7149

View on ClinicalTrials.gov